Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression
- PMID: 28353608
- PMCID: PMC5380292
- DOI: 10.1097/MD.0000000000006514
Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression
Abstract
This study aimed to investigate prospective memory impairment in patients with breast cancer with different expression of hormone receptors, including the estrogen receptor (ER) and the progesterone receptor (PR).A total of 120 patients with breast cancer who underwent chemotherapy following surgery were divided into 2 groups. The A group included 60 patients with ER/PR status, and the B group included 60 patients with ER/PR status. After 6 cycles of postoperative adjuvant chemotherapy, all patients were administered neuropsychological and prospective memory tests, such as the Mini-Mental State Examination (MMSE), verbal fluency test (VFT), and digit span test (DST), as well as examination of event-based prospective memory (EBPM) and time-based prospective memory (TBPM).As the neuropsychological background test results showed, there were no significant differences in MMSE, DST, and TBPM scores (*:P > 0.05) between patients with breast cancer in the ER/PR and ER/PR groups, while the VFT and EBPM scores were significantly greater in patients with breast cancer with ER/PR status than in those with ER/PR status (**: P < 0.01), indicating that patients with ER/PR status have significant impairment in EBPM, although not in TBPM.The results of the present study indicate that different hormone receptor expression in patients with breast cancer may be associated with heterogeneity of chemotherapy-induced prospective memory impairment.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Similar articles
-
Chemotherapy-induced prospective memory impairment in patients with breast cancer.Psychooncology. 2013 Oct;22(10):2391-5. doi: 10.1002/pon.3291. Epub 2013 May 15. Psychooncology. 2013. PMID: 23674402
-
Catechol-O-Methyltransferase Gene Polymorphisms and the Risk of Chemotherapy-Induced Prospective Memory Impairment in Breast Cancer Patients with Varying Tumor Hormonal Receptor Expression.Med Sci Monit. 2020 Sep 28;26:e923567. doi: 10.12659/MSM.923567. Med Sci Monit. 2020. PMID: 32985495 Free PMC article.
-
Prospective memory impairment following whole brain radiotherapy in patients with metastatic brain cancer.Cancer Med. 2018 Oct;7(10):5315-5321. doi: 10.1002/cam4.1784. Epub 2018 Sep 27. Cancer Med. 2018. PMID: 30259694 Free PMC article.
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
-
Adjuvant chemotherapy in luminal breast cancers.Breast. 2011 Oct;20 Suppl 3:S128-31. doi: 10.1016/S0960-9776(11)70309-5. Breast. 2011. PMID: 22015279 Review.
Cited by
-
GSK3β rs3107669 polymorphism implicates chemotherapy-associated retrospective memory deficits in breast cancer survivors.Am J Cancer Res. 2023 Oct 15;13(10):4961-4975. eCollection 2023. Am J Cancer Res. 2023. PMID: 37970370 Free PMC article.
-
A scoping review of cognitive assessment tools and domains for chemotherapy-induced cognitive impairments in cancer survivors.Front Hum Neurosci. 2023 Feb 20;17:1063674. doi: 10.3389/fnhum.2023.1063674. eCollection 2023. Front Hum Neurosci. 2023. PMID: 36891148 Free PMC article. Review.
-
Sleep-dependent memory consolidation in breast cancer: Use of a virtual reality prospective memory task.Front Neurosci. 2022 Sep 7;16:908268. doi: 10.3389/fnins.2022.908268. eCollection 2022. Front Neurosci. 2022. PMID: 36161169 Free PMC article.
-
COMT rs737865 mediates chemobrain in breast cancer patients with various levels of Ki-67.Am J Cancer Res. 2022 Jul 15;12(7):3185-3197. eCollection 2022. Am J Cancer Res. 2022. PMID: 35968333 Free PMC article.
-
The COMT Genetic Factor Regulates Chemotherapy-Related Prospective Memory Impairment in Survivors With HER2-/+ Breast Cancer.Front Oncol. 2022 Feb 8;12:816923. doi: 10.3389/fonc.2022.816923. eCollection 2022. Front Oncol. 2022. PMID: 35211407 Free PMC article.
References
-
- Park JH, Bae SH, Jung YS, et al. [Prevalence and characteristics of chemotherapy-related cognitive impairment in patients with breast cancer]. J Korean Acad Nurs 2015;45:118–28. - PubMed
-
- Pullens MJ, De Vries J, Van Warmerdam LJ, et al. Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology 2013;22:1783–9. - PubMed
-
- Rey D, Bouhnik AD, Mancini J, et al. Self-reported cognitive impairment after breast cancer treatment in young women from the ELIPPSE40 cohort: the long-term impact of chemotherapy. Breast J 2012;18:406–14. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
